Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biohit Oyj Director's Dealing 2017

Feb 23, 2017

3304_rns_2017-02-23_e1d8cee1-1ea4-4395-9915-28f849630f78.html

Director's Dealing

Open in viewer

Opens in your device viewer

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, February 23, 2017 at 3:50 pm local time
(EET)

____________________________________________

Person subject to the notification requirement

Name: Korpela, Semi

Position: Chief Executive Officer

Issuer: Biohit Oyj

LEI: 74370089ATTSNBXJVT29

Notification type: INITIAL NOTIFICATION

Reference number: 74370089ATTSNBXJVT29_20170223141702_5

____________________________________________

Transaction date: 2017-02-20

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000219324

Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS)

(X) Linked to stock option programme

Transaction Details

(1): Volume: 13933 Unit price: 3,40920 EUR

(2): Volume: 2776 Unit price: 3,70400 EUR

(3): Volume: 15299 Unit price: 3,51260 EUR

(4): Volume: 9810 Unit price: 2,27660 EUR

(5): Volume: 3962 Unit price: 3,51260 EUR

Aggregated transactions

(5): Volume: 45780 Volume weighted average price: 3.22788 EUR

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
[email protected]
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com